会員になる

カート (0)

DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか？ or パスワードをお忘れですか？

Not a Member?

アカウントを作成して参加。

DoubleTree Bethesdan

2019年9月23日 (月) 午前 7:00 - 2019年9月24日 (火) 午後 5:00

8120 Wisconsin Avenue, , Bethesda, MD 20814 , USA

Biosimilars Conference

戻る Agenda

Session 6: What’s the Value to Patients and What Challenges Exist to Access?

Session Chair(s)

Mary Jo Carden, JD, RPh

Head, Policy

Sandoz, Inc., United States

Biosimilars offer safe, effective, and more affordable alternatives to patients who use biologic medications for managing chronic conditions. To date, biosimilars have not necessarily achieved the expected goals of allowing patients to have access to more affordable biologic medications. This session will enable participates to hear the patient perspective on biosimilars and recommendations for overcoming current challenges and barriers. Issues considered will include potential cost savings of biosimilars to patients and the health care system, the implications of how access to biosimilars may improve adherence to biologics, and ways that savings from biosimilars may improve patient care through better access to services and patient support.

Learning Objective : At the conclusion of this session, participants should be able to:
Describe the current environment in the United States related to patient access to biosimilars
Identify challenges in patient access to biosimilars including regulatory issues, payment issues, and education
Describe 1-2 ways that current challenges may be improved

Speaker(s)

Implications to Biosimilar Access for Patients with Arthritis

Benjamin Chandhok

Arthritis Foundation, United States

Senior Director, State Legislative Affairs

How Can Biosimilars Benefit Patients with Cancer and What Are Challenges to Access?

Laura Lasiter

Friends of Cancer Research, United States

Science Policy Analyst